8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Inhibition of FAAH is hypothesized to reduce the excitability of urinary tract afferents including nociceptors.

          Related collections

          Author and article information

          Journal
          Urology
          Urology
          Elsevier BV
          1527-9995
          0090-4295
          May 2017
          : 103
          Affiliations
          [1 ] Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen, Germany.
          [2 ] Astellas Pharma Europe B.V., Leiden, The Netherlands. Electronic address: olivier.vantill@astellas.com.
          [3 ] Astellas Pharma Europe B.V., Leiden, The Netherlands.
          [4 ] Biostatistics Department, University of Liverpool, Liverpool, United Kingdom.
          [5 ] Centrum Medyczne Szpital Sw Rodziny Sp z o.o., Lodz, Poland.
          [6 ] Stradins Clinical University Hospital, Riga, Latvia.
          [7 ] Androgeos, Praha, Czech Republic.
          [8 ] Vilnius University Hospital "Santariskiu Klinikos" Urology Centre, Vilnius, Lithuania.
          [9 ] Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
          [10 ] Department of Urology, Queen's University, Kingston, ON, Canada.
          Article
          S0090-4295(17)30173-5
          10.1016/j.urology.2017.02.029
          28254462
          57ea500f-c22e-4ee8-b635-a4aab7a67371
          History

          Comments

          Comment on this article